Core Insights - Firefly Neuroscience, Inc. has achieved a greater than 20-fold expansion of its commercial footprint and a 33-fold increase in EEG/ERP brain scan volumes, indicating significant growth in its operations and market presence [1][2] - The company ended 2025 with 99 commercial partners, completing over 10,800 EEG/ERP brain scans, reflecting year-over-year growth of 1,880% in partner sites and 3,227% in clinical assessments since the end of 2024 [2] - Firefly aims to leverage AI and EEG/ERP technology to transform neuroscience and clinical development, with a focus on cognitive brain biomarker discovery [3] Company Overview - Firefly is an AI company focused on developing innovative solutions to enhance brain health outcomes for patients with neurological and mental disorders [1] - The company possesses the world's largest standardized EEG/ERP repository, with over 191,000 brain scans, which supports its advanced analytics technology [4] - Firefly's technology is FDA-510(k)-cleared and has the potential to revolutionize diagnostic and treatment monitoring methods for various conditions, including depression and ADHD [4]
Firefly Progresses Toward Development and Commercial Launch of its Foundation Model of the Human Brain Powered by NVIDIA GPU Acceleration